Live Earnings Conference Call: Neurocrine Biosciences will host a live Q1 2025 earnings call on May 5, 2025 at 4:30PM ET. Get details.

Neurocrine Biosciences (NBIX) Financials

$109.93 +0.25 (+0.23%)

As of 11:13 AM Eastern

Compare

Annual Income Statements for Neurocrine Biosciences

This table shows Neurocrine Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-89	-141	-143	21	37	407	90	155	250	341
Consolidated Net Income / (Loss)	-89	-141	-143	21	37	407	90	155	250	341
Net Income / (Loss) Continuing Operations	-89	-141	-143	21	37	407	90	155	250	341
Total Pre-Tax Income	-89	-141	-143	22	47	107	101	214	332	486
Total Operating Income	-94	-147	-131	37	72	163	103	249	251	571
Total Gross Profit	20	15	160	446	781	1,036	1,119	1,466	1,847	2,321
Total Revenue	20	15	162	451	788	1,046	1,134	1,489	1,887	2,355
Operating Revenue	20	15	162	451	788	1,046	1,134	1,489	1,887	2,355
Total Cost of Revenue	0.00	0.00	1.25	4.90	7.40	10	14	23	40	34
Operating Cost of Revenue	0.00	0.00	1.25	4.90	7.40	10	14	23	40	34
Total Operating Expenses	114	162	292	410	708	873	1,017	1,217	1,597	1,751
Selling, General & Admin Expense	32	68	170	249	354	433	583	753	888	1,007
Research & Development Expense	81	94	122	161	354	440	433	464	709	744
Total Other Income / (Expense), net	5.27	6.28	-11	-15	-26	-56	-1.10	-35	81	-85
Interest Expense	0.00	0.00	20	31	32	51	26	70	0.00	138
Interest & Investment Income	1.93	6.28	8.34	16	19	13	3.80	4.10	53	91
Other Income / (Expense), net	3.35	-	0.00	0.00	-13	-18	21	31	28	-37
Income Tax Expense	-	0.00	-	0.70	9.50	-301	12	59	82	145
Basic Earnings per Share	($1.05)	($1.63)	($1.62)	$0.23	$0.40	$4.38	$0.95	$1.61	$2.56	$3.40
Weighted Average Basic Shares Outstanding	84.50M	86.71M	88.09M	90.20M	91.60M	93.10M	94.60M	95.80M	97.70M	100.40M
Diluted Earnings per Share	($1.05)	($1.63)	($1.62)	$0.22	$0.39	$4.16	$0.92	$1.56	$2.47	$3.29
Weighted Average Diluted Shares Outstanding	84.50M	86.71M	88.09M	95.40M	95.70M	97.80M	97.90M	98.90M	101M	103.70M
Weighted Average Basic & Diluted Shares Outstanding	84.70M	86.60M	88M	91.80M	92.50M	93.94M	95.24M	96.59M	99.51M	99.70M

This table shows Neurocrine Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	69	89	-77	96	83	148	43	65	130	103
Consolidated Net Income / (Loss)	69	89	-77	96	83	148	43	65	130	103
Net Income / (Loss) Continuing Operations	69	89	-77	96	83	148	43	65	130	103
Total Pre-Tax Income	98	118	-103	122	116	198	35	99	190	163
Total Operating Income	88	103	-114	74	141	150	99	145	184	142
Total Gross Profit	382	404	412	441	488	507	508	581	614	618
Total Revenue	388	412	420	453	499	515	515	590	622	628
Operating Revenue	388	412	420	453	499	515	515	590	622	628
Total Cost of Revenue	6.10	7.70	8.50	12	11	8.50	7.50	9.20	8.00	9.30
Operating Cost of Revenue	6.10	7.70	8.50	12	11	8.50	7.50	9.20	8.00	9.30
Total Operating Expenses	294	301	526	368	346	356	409	436	430	476
Selling, General & Admin Expense	186	183	243	222	204	219	243	242	234	288
Research & Development Expense	108	118	283	146	142	138	165	194	196	189
Total Other Income / (Expense), net	10	15	11	48	-26	48	-65	-47	6.50	21
Interest Expense	1.20	-6.00	1.10	0.00	0.00	-1.10	1.10	50	0.00	88
Interest & Investment Income	0.20	1.30	9.80	11	15	18	23	23	23	21
Other Income / (Expense), net	11	7.20	2.20	37	-40	29	-87	-20	-17	87
Income Tax Expense	29	29	-27	26	33	51	-8.90	34	61	60
Basic Earnings per Share	$0.72	$0.92	($0.79)	$0.98	$0.85	$1.52	$0.43	$0.64	$1.28	$1.05
Weighted Average Basic Shares Outstanding	95.80M	95.80M	97.10M	97.60M	97.90M	97.70M	99.80M	100.80M	101.10M	100.40M
Diluted Earnings per Share	$0.69	$0.91	($0.79)	$0.95	$0.82	$1.49	$0.42	$0.63	$1.24	$1.00
Weighted Average Diluted Shares Outstanding	99M	98.90M	97.10M	100.20M	101.10M	101M	103.60M	103.90M	104.30M	103.70M
Weighted Average Basic & Diluted Shares Outstanding	96.13M	96.59M	97.57M	97.65M	98.25M	99.51M	100.64M	100.98M	101.25M	99.70M

This table details how cash moves in and out of Neurocrine Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	43	9.16	171	-112	-32	75	154	-73	-12	-18
Net Cash From Operating Activities	-38	-106	-94	101	147	229	257	339	390	595
Net Cash From Continuing Operating Activities	-38	-106	-94	101	147	229	257	339	390	595
Net Income / (Loss) Continuing Operations	-89	-141	-143	21	37	407	90	155	250	341
Consolidated Net Income / (Loss)	-89	-141	-143	21	37	407	90	155	250	341
Depreciation Expense	1.01	1.45	2.40	4.00	7.40	8.60	11	15	18	24
Amortization Expense	6.03	3.52	14	19	20	21	25	4.20	-15	-23
Non-Cash Adjustments To Reconcile Net Income	25	24	43	58	88	136	113	212	166	371
Changes in Operating Assets and Liabilities, net	19	5.49	-10	-0.70	-6.00	-345	18	-47	-29	-118
Net Cash From Investing Activities	-196	113	-251	-243	-211	4.10	-130	-177	-467	-127
Net Cash From Continuing Investing Activities	-196	113	-251	-243	-211	4.10	-130	-177	-467	-127
Purchase of Property, Plant & Equipment	-1.93	-4.11	-6.94	-25	-15	-11	-23	-17	-28	-38
Acquisitions	-	-	-	-	-	0.00	0.00	-43	0.00	0.00
Purchase of Investments	-449	-299	-583	-546	-866	-736	-805	-629	-1,411	-1,056
Sale and/or Maturity of Investments	255	416	339	328	670	751	698	511	972	968
Net Cash From Financing Activities	277	2.39	517	30	32	-158	27	-234	65	-487
Net Cash From Continuing Financing Activities	277	2.39	517	30	32	-158	27	-234	65	-487
Repayment of Debt	-	-	-	0.00	0.00	-187	-0.10	-279	0.00	-309
Repurchase of Common Equity	-	-	-	-	-	-	-	0.00	0.00	-300
Issuance of Common Equity	277	2.39	14	30	32	29	28	45	65	122
Effect of Exchange Rate Changes	-	-	-	-	-	0.00	0.00	-1.30	0.30	0.00
Cash Interest Paid	0.00	0.00	6.24	12	12	12	8.60	6.60	3.80	1.60
Cash Income Taxes Paid	0.00	-	0.00	0.00	0.50	15	5.10	14	52	218

This table details how cash moves in and out of Neurocrine Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	49	51	-159	57	134	-43	145	-257	209	-116
Net Cash From Operating Activities	99	143	-125	180	212	124	130	65	158	243
Net Cash From Continuing Operating Activities	99	143	-125	180	212	124	130	65	158	243
Net Income / (Loss) Continuing Operations	69	89	-77	96	83	148	43	65	130	103
Consolidated Net Income / (Loss)	69	89	-77	96	83	148	43	65	130	103
Depreciation Expense	4.00	3.90	4.10	4.20	4.60	4.90	5.30	6.40	5.60	6.20
Amortization Expense	0.20	3.20	-1.20	-3.00	-5.10	-5.50	-6.20	-6.10	-5.60	-4.70
Non-Cash Adjustments To Reconcile Net Income	32	36	38	31	88	9.10	132	127	58	54
Changes in Operating Assets and Liabilities, net	-5.90	11	-89	52	42	-33	-44	-127	-30	84
Net Cash From Investing Activities	-61	-116	-42	-126	-97	-202	-55	-28	25	-68
Net Cash From Continuing Investing Activities	-61	-116	-42	-126	-97	-202	-55	-28	25	-68
Purchase of Property, Plant & Equipment	1.70	-1.80	-8.50	-6.80	-7.60	-5.40	-11	-12	-8.10	-7.30
Purchase of Investments	-134	-233	-238	-324	-363	-487	-320	-192	-233	-312
Sale and/or Maturity of Investments	71	162	204	205	273	291	276	175	265	251
Net Cash From Financing Activities	11	25	8.20	2.90	19	35	70	-293	26	-290
Net Cash From Continuing Financing Activities	11	25	8.20	2.90	19	35	70	-293	26	-290
Issuance of Common Equity	11	25	8.20	2.90	19	35	70	16	26	10
Effect of Exchange Rate Changes	-	-	-	-	-	0.30	-	-	-	-0.30
Cash Income Taxes Paid	1.20	10	0.20	3.20	1.60	47	0.20	93	52	73

This table presents Neurocrine Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	475	365	818	993	1,306	1,735	2,073	2,369	3,251	3,719
Total Current Assets	384	310	555	738	831	1,016	973	1,454	1,607	1,725
Cash & Equivalents	74	83	255	142	112	187	341	263	251	233
Short-Term Investments	305	224	261	509	558	614	371	726	781	843
Accounts Receivable	-	0.00	31	57	127	157	186	350	439	479
Inventories, net	-	-	1.02	11	17	28	31	35	38	57
Other Current Assets	4.88	3.09	6.84	19	17	30	46	79	98	112
Plant, Property, & Equipment, net	3.43	6.27	11	34	42	45	59	59	71	83
Total Noncurrent Assets	87	48	252	222	433	674	1,041	857	1,574	1,911
Long-Term Investments	82	43	247	216	356	265	624	299	849	864
Intangible Assets	-	-	-	-	-	-	0.00	37	36	37
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	0.00	319	315	306	363	486
Other Noncurrent Operating Assets	-	-	-	-	74	89	102	214	326	525
Total Liabilities & Shareholders' Equity	475	365	818	993	1,306	1,735	2,073	2,369	3,251	3,719
Total Liabilities	50	50	445	512	669	609	699	661	1,019	1,129
Total Current Liabilities	26	30	54	88	565	187	246	538	655	508
Short-Term Debt	-	-	-	-	409	-	0.00	169	170	0.00
Accounts Payable	2.56	26	54	86	141	169	226	348	449	462
Other Current Liabilities	0.43	0.24	0.91	1.86	15	18	20	21	36	46
Total Noncurrent Liabilities	25	20	391	424	104	422	453	123	365	621
Other Noncurrent Operating Liabilities	13	8.10	8.04	36	104	104	118	123	365	621
Total Equity & Noncontrolling Interests	424	315	372	481	637	1,126	1,374	1,708	2,232	2,590
Total Preferred & Common Equity	424	315	372	481	637	1,126	1,374	1,708	2,232	2,590
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	424	315	372	481	637	1,126	1,374	1,708	2,232	2,590
Common Stock	1,341	1,372	1,573	1,660	1,768	1,850	2,012	2,123	2,382	2,555
Retained Earnings	-915	-1,056	-1,199	-1,178	-1,133	-725	-636	-407	-157	29
Accumulated Other Comprehensive Income / (Loss)	-0.98	-0.32	-1.85	-1.93	1.40	1.80	-1.70	-7.90	7.00	5.80

This table presents Neurocrine Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	2,143	2,360	2,613	2,848	3,472	3,305	3,535
Total Current Assets	1,206	1,433	1,497	1,650	1,799	1,670	1,877
Cash & Equivalents	212	104	160	294	396	140	349
Short-Term Investments	587	791	817	801	814	899	879
Accounts Receivable	301	392	388	418	451	468	481
Inventories, net	37	33	32	29	37	43	46
Other Current Assets	68	113	101	108	101	120	122
Plant, Property, & Equipment, net	61	63	66	69	75	80	80
Total Noncurrent Assets	877	864	1,051	1,130	1,598	1,555	1,578
Long-Term Investments	363	245	343	455	864	638	771
Intangible Assets	-	37	37	35	34	34	35
Noncurrent Deferred & Refundable Income Taxes	319	337	379	383	378	420	454
Other Noncurrent Operating Assets	195	245	292	257	322	464	319
Total Liabilities & Shareholders' Equity	2,143	2,360	2,613	2,848	3,472	3,305	3,535
Total Liabilities	599	675	760	846	1,086	796	816
Total Current Liabilities	485	374	583	692	713	399	430
Short-Term Debt	169	0.00	170	170	123	0.00	0.00
Accounts Payable	298	356	392	503	417	359	393
Other Current Liabilities	18	18	21	19	173	40	37
Total Noncurrent Liabilities	114	301	178	155	373	397	386
Other Noncurrent Operating Liabilities	114	132	178	155	373	397	386
Total Equity & Noncontrolling Interests	1,545	1,685	1,853	2,002	2,386	2,509	2,719
Total Preferred & Common Equity	1,545	1,685	1,853	2,002	2,386	2,509	2,719
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,545	1,685	1,853	2,002	2,386	2,509	2,719
Common Stock	2,054	2,171	2,242	2,309	2,497	2,555	2,623
Retained Earnings	-496	-483	-388	-305	-114	-49	81
Accumulated Other Comprehensive Income / (Loss)	-14	-2.70	-1.10	-1.70	3.30	2.50	15

This table displays calculated financial ratios and metrics derived from Neurocrine Biosciences' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	-24.12%	977.51%	179.16%	74.67%	32.71%	8.38%	31.34%	26.76%	24.81%
EBITDA Growth	-48.21%	-69.89%	18.95%	151.72%	45.73%	101.49%	-9.30%	88.11%	-5.62%	89.27%
EBIT Growth	-48.53%	-62.20%	10.86%	128.01%	61.14%	145.03%	-15.07%	126.74%	-0.18%	90.98%
NOPAT Growth	-46.25%	-56.44%	10.86%	138.74%	61.52%	981.56%	-85.44%	98.57%	4.89%	112.38%
Net Income Growth	-46.89%	-58.65%	-1.03%	114.80%	75.36%	1,000.81%	-78.00%	72.43%	61.62%	36.68%
EPS Growth	-29.63%	-55.24%	0.61%	113.58%	77.27%	966.67%	-77.88%	69.57%	58.33%	33.20%
Operating Cash Flow Growth	19.40%	-179.45%	11.16%	207.49%	44.97%	55.44%	12.25%	32.32%	14.88%	52.71%
Free Cash Flow Firm Growth	-8.29%	-103.14%	-2.33%	111.93%	198.02%	586.85%	-63.59%	-137.11%	826.43%	6.40%
Invested Capital Growth	-53.16%	2.78%	36.26%	87.87%	619.48%	2,203.66%	-1.16%	57.61%	-11.45%	24.60%
Revenue Q/Q Growth	0.00%	0.00%	140.84%	8.92%	16.68%	0.36%	5.99%	7.20%	5.79%	5.02%
EBITDA Q/Q Growth	-12.84%	-16.43%	35.32%	5.71%	48.75%	20.23%	-29.58%	58.84%	26.88%	10.53%
EBIT Q/Q Growth	-12.73%	-14.73%	30.66%	13.24%	78.08%	25.26%	-37.55%	73.47%	32.62%	10.23%
NOPAT Q/Q Growth	-12.25%	-11.76%	30.66%	32.62%	27.06%	392.97%	-84.83%	132.41%	21.91%	-6.44%
Net Income Q/Q Growth	-12.49%	-12.20%	26.56%	112.55%	75.63%	336.08%	-79.86%	165.46%	30.73%	-11.56%
EPS Q/Q Growth	-11.70%	-10.88%	27.35%	0.00%	0.00%	320.20%	-79.87%	168.97%	30.69%	-12.96%
Operating Cash Flow Q/Q Growth	0.28%	-18.30%	43.36%	10.84%	47.01%	-1.30%	-26.04%	69.19%	-4.76%	24.98%
Free Cash Flow Firm Q/Q Growth	-4.19%	-12.78%	31.48%	49.76%	4,542.06%	118.33%	-67.42%	68.70%	203.58%	-17.47%
Invested Capital Q/Q Growth	-14.55%	-11.97%	-96.23%	-162.11%	-66.90%	571.05%	3.21%	6.65%	-16.25%	-9.86%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	99.22%	98.91%	99.06%	99.03%	98.74%	98.44%	97.90%	98.56%
EBITDA Margin	-423.98%	-949.33%	-71.41%	13.23%	11.04%	16.76%	14.03%	20.09%	14.96%	22.69%
Operating Margin	-476.51%	-982.48%	-81.27%	8.16%	9.17%	15.58%	9.04%	16.73%	13.30%	24.22%
EBIT Margin	-459.59%	-982.48%	-81.27%	8.16%	7.52%	13.89%	10.89%	18.79%	14.80%	22.65%
Profit (Net Income) Margin	-449.84%	-940.60%	-88.19%	4.68%	4.69%	38.94%	7.90%	10.38%	13.23%	14.49%
Tax Burden Percent	100.00%	100.00%	100.00%	96.79%	79.57%	381.72%	88.36%	72.23%	75.19%	70.23%
Interest Burden Percent	97.88%	95.74%	108.51%	59.24%	78.41%	73.43%	82.17%	76.45%	118.90%	91.11%
Effective Tax Rate	0.00%	0.00%	0.00%	3.21%	20.43%	-281.72%	11.64%	27.77%	24.81%	29.77%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	868.82%	315.68%	24.11%	37.40%	34.00%	68.46%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	872.54%	347.08%	24.23%	39.79%	29.69%	71.71%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	-862.20%	-269.48%	-16.95%	-27.37%	-21.33%	-54.31%
Return on Equity (ROE)	-28.09%	-38.17%	-41.50%	4.95%	6.62%	46.20%	7.17%	10.03%	12.68%	14.16%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	231.54%	132.32%	25.29%	-7.33%	46.15%	46.56%
Operating Return on Assets (OROA)	-25.31%	-35.09%	-22.21%	4.06%	5.16%	9.56%	6.48%	12.60%	9.94%	15.31%
Return on Assets (ROA)	-24.78%	-33.60%	-24.11%	2.33%	3.22%	26.79%	4.71%	6.96%	8.89%	9.79%
Return on Common Equity (ROCE)	-28.09%	-38.17%	-41.50%	4.95%	6.62%	46.20%	7.17%	10.03%	12.68%	14.16%
Return on Equity Simple (ROE_SIMPLE)	-20.95%	-44.81%	-38.30%	4.39%	5.81%	36.17%	6.52%	9.05%	11.19%	13.18%
Net Operating Profit after Tax (NOPAT)	-66	-103	-92	36	58	622	91	180	189	401
NOPAT Margin	-333.56%	-687.74%	-56.89%	7.89%	7.30%	59.49%	7.99%	12.08%	10.00%	17.01%
Net Nonoperating Expense Percent (NNEP)	-6.54%	-9.23%	-13.42%	-3.29%	-3.72%	-31.40%	-0.11%	-2.39%	4.31%	-3.25%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	9.58%	7.85%	15.47%
Cost of Revenue to Revenue	0.00%	0.00%	0.78%	1.09%	0.94%	0.97%	1.26%	1.56%	2.10%	1.44%
SG&A Expenses to Revenue	164.30%	453.87%	105.12%	55.16%	44.93%	41.43%	51.46%	50.56%	47.04%	42.76%
R&D to Revenue	412.22%	628.61%	75.38%	35.59%	44.96%	42.02%	38.24%	31.15%	37.57%	31.57%
Operating Expenses to Revenue	576.51%	1,082.48%	180.50%	90.76%	89.89%	83.45%	89.70%	81.72%	84.60%	74.33%
Earnings before Interest and Taxes (EBIT)	-91	-147	-131	37	59	145	123	280	279	533
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-84	-142	-115	60	87	175	159	299	282	534
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	11.49	10.68	18.45	13.47	15.54	7.95	5.88	6.72	5.80	5.34
Price to Tangible Book Value (P/TBV)	11.49	10.68	18.45	13.47	15.54	7.95	5.88	6.87	5.89	5.41
Price to Revenue (P/Rev)	246.66	224.13	42.48	14.35	12.56	8.56	7.13	7.71	6.86	5.87
Price to Earnings (P/E)	0.00	0.00	0.00	306.90	267.54	21.99	90.18	74.32	51.84	40.49
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.33%	0.37%	4.55%	1.11%	1.35%	1.93%	2.47%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	565.97	21.72	18.96	17.61	21.56	18.30
Enterprise Value to Revenue (EV/Rev)	223.30	200.74	40.05	13.29	11.78	7.85	6.25	6.96	5.95	5.04
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	100.46	106.69	46.82	44.52	34.65	39.80	22.23
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	162.97	156.52	56.48	57.37	37.04	40.22	22.27
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	168.37	161.34	13.19	78.16	57.62	59.55	29.65
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	59.14	63.14	35.92	27.60	30.53	28.81	19.95
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	470.69	244.44	31.47	74.54	0.00	43.88	43.61
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.99	0.81	0.64	0.28	0.24	0.10	0.08	0.00
Long-Term Debt to Equity	0.00	0.00	0.99	0.81	0.00	0.28	0.24	0.00	0.00	0.00
Financial Leverage	-1.11	-1.11	-1.10	-1.03	-0.99	-0.78	-0.70	-0.69	-0.72	-0.76
Leverage Ratio	1.13	1.14	1.72	2.12	2.06	1.72	1.52	1.44	1.43	1.45
Compound Leverage Factor	1.11	1.09	1.87	1.26	1.61	1.27	1.25	1.10	1.70	1.32
Debt to Total Capital	0.00%	0.00%	49.83%	44.69%	39.09%	22.01%	19.61%	9.02%	7.08%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	39.09%	0.00%	0.00%	9.02%	7.08%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	49.83%	44.69%	0.00%	22.01%	19.61%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	50.17%	55.31%	60.91%	77.99%	80.39%	90.98%	92.92%	100.00%
Debt to EBITDA	0.00	0.00	-3.20	6.51	4.70	1.81	2.11	0.57	0.60	0.00
Net Debt to EBITDA	0.00	0.00	3.41	-8.01	-7.10	-4.27	-6.29	-3.74	-6.06	0.00
Long-Term Debt to EBITDA	0.00	0.00	-3.20	6.51	0.00	1.81	2.11	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	-4.02	10.91	7.11	0.51	3.70	0.94	0.90	0.00
Net Debt to NOPAT	0.00	0.00	4.28	-13.43	-10.73	-1.20	-11.05	-6.22	-9.07	0.00
Long-Term Debt to NOPAT	0.00	0.00	-4.02	10.91	0.00	0.51	3.70	0.00	0.00	0.00
Altman Z-Score	55.75	35.75	7.60	7.28	8.66	9.70	7.68	11.67	8.77	8.86
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	14.94	10.21	10.20	8.36	1.47	5.45	3.96	2.70	2.45	3.40
Quick Ratio	14.75	10.11	10.05	8.03	1.41	5.14	3.65	2.49	2.25	3.06
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-51	-104	-107	13	38	261	95	-35	256	272
Operating Cash Flow to CapEx	-1,973.87%	-2,592.94%	-1,360.61%	408.87%	1,000.00%	2,096.33%	1,096.15%	2,056.97%	1,377.74%	1,558.64%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-5.47	0.42	1.19	5.09	3.68	-0.50	0.00	1.97
Operating Cash Flow to Interest Expense	0.00	0.00	-4.83	3.32	4.59	4.46	9.94	4.85	0.00	4.30
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-5.19	2.51	4.13	4.25	9.03	4.61	0.00	4.03
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.06	0.04	0.27	0.50	0.69	0.69	0.60	0.67	0.67	0.68
Accounts Receivable Turnover	0.00	0.00	0.00	10.19	8.57	7.37	6.62	5.56	4.78	5.13
Inventory Turnover	0.00	0.00	0.00	0.82	0.53	0.45	0.49	0.71	1.08	0.71
Fixed Asset Turnover	6.66	3.09	18.92	20.20	20.80	24.18	21.97	25.40	29.17	30.71
Accounts Payable Turnover	0.00	0.00	0.03	0.07	0.07	0.07	0.07	0.08	0.10	0.07
Days Sales Outstanding (DSO)	0.00	0.00	0.00	35.81	42.61	49.50	55.16	65.65	76.33	71.16
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	442.77	694.59	818.54	746.59	516.03	337.42	513.68
Days Payable Outstanding (DPO)	0.00	0.00	11,599.37	5,210.45	5,615.01	5,601.49	5,034.70	4,510.58	3,661.03	4,886.71
Cash Conversion Cycle (CCC)	0.00	0.00	-11,599.37	-4,731.87	-4,877.81	-4,733.44	-4,232.95	-3,928.90	-3,247.28	-4,301.86
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-42	-41	-26	-3.16	16	378	373	589	521	649
Invested Capital Turnover	-0.57	-0.36	-4.83	-30.91	119.02	5.31	3.02	3.10	3.40	4.02
Increase / (Decrease) in Invested Capital	-15	1.17	15	23	20	361	-4.40	215	-67	128
Enterprise Value (EV)	4,414	3,011	6,473	5,997	9,282	8,207	7,079	10,363	11,235	11,880
Market Capitalization	4,876	3,362	6,866	6,476	9,899	8,955	8,080	11,482	12,946	13,820
Book Value per Share	$4.92	$3.62	$4.21	$5.30	$6.92	$12.05	$14.48	$17.76	$22.72	$25.58
Tangible Book Value per Share	$4.92	$3.62	$4.21	$5.30	$6.92	$12.05	$14.48	$17.38	$22.36	$25.22
Total Capital	424	315	742	869	1,046	1,444	1,709	1,877	2,402	2,590
Total Debt	0.00	0.00	370	388	409	318	335	169	170	0.00
Total Long-Term Debt	0.00	0.00	370	388	0.00	318	335	0.00	0.00	0.00
Net Debt	-462	-351	-394	-478	-617	-748	-1,001	-1,119	-1,711	-1,940
Capital Expenditures (CapEx)	1.93	4.10	6.93	25	15	11	23	17	28	38
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-21	-27	-15	-1.37	4.00	29	16	96	91	141
Debt-free Net Working Capital (DFNWC)	358	280	500	650	675	830	727	1,085	1,122	1,217
Net Working Capital (NWC)	358	280	500	650	266	830	727	916	952	1,217
Net Nonoperating Expense (NNE)	23	38	51	15	21	215	0.97	25	-61	59
Net Nonoperating Obligations (NNO)	-466	-356	-398	-484	-621	-748	-1,001	-1,119	-1,711	-1,940
Total Depreciation and Amortization (D&A)	7.04	4.97	16	23	28	30	36	19	3.00	0.90
Debt-free, Cash-free Net Working Capital to Revenue	-105.38%	-182.15%	-9.55%	-0.30%	0.51%	2.74%	1.39%	6.44%	4.81%	5.98%
Debt-free Net Working Capital to Revenue	1,812.73%	1,866.85%	309.66%	143.96%	85.59%	79.33%	64.14%	72.90%	59.47%	51.67%
Net Working Capital to Revenue	1,812.73%	1,866.85%	309.66%	143.96%	33.71%	79.33%	64.14%	61.52%	50.46%	51.67%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.05)	($1.63)	($1.62)	$0.23	$0.40	$4.38	$0.95	$1.61	$2.56	$3.40
Adjusted Weighted Average Basic Shares Outstanding	84.50M	86.71M	88.09M	90.24M	91.63M	93.10M	94.60M	95.80M	97.70M	100.40M
Adjusted Diluted Earnings per Share	($1.05)	($1.63)	($1.62)	$0.22	$0.39	$4.16	$0.92	$1.56	$2.47	$3.29
Adjusted Weighted Average Diluted Shares Outstanding	84.50M	86.71M	88.09M	95.39M	95.73M	97.80M	97.90M	98.90M	101M	103.70M
Adjusted Basic & Diluted Earnings per Share	($1.05)	$0.00	($1.62)	$0.23	$0.40	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	86.45M	87.11M	89.27M	90.82M	92.29M	93.94M	95.24M	96.59M	99.51M	99.70M
Normalized Net Operating Profit after Tax (NOPAT)	-66	-103	-92	36	58	114	91	180	189	401
Normalized NOPAT Margin	-333.56%	-687.74%	-56.89%	7.89%	7.30%	10.91%	7.99%	12.08%	10.00%	17.01%
Pre Tax Income Margin	-449.84%	-940.60%	-88.19%	4.83%	5.90%	10.20%	8.95%	14.37%	17.60%	20.63%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-6.73	1.21	1.85	2.84	4.78	4.00	0.00	3.85
NOPAT to Interest Expense	0.00	0.00	-4.71	1.17	1.80	12.15	3.51	2.57	0.00	2.89
EBIT Less CapEx to Interest Expense	0.00	0.00	-7.08	0.39	1.39	2.63	3.88	3.76	0.00	3.58
NOPAT Less CapEx to Interest Expense	0.00	0.00	-5.07	0.35	1.34	11.94	2.60	2.33	0.00	2.62
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	87.90%

This table displays calculated financial ratios and metrics derived from Neurocrine Biosciences' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	31.05%	32.05%	35.35%	19.70%	28.59%	25.05%	22.57%	30.37%	24.72%	21.84%
EBITDA Growth	137.01%	1,605.80%	-508.61%	117.25%	-2.42%	51.83%	110.36%	12.22%	65.90%	28.88%
EBIT Growth	172.45%	1,500.00%	-586.96%	134.46%	2.22%	62.12%	110.89%	13.17%	65.08%	27.61%
NOPAT Growth	87.14%	407.18%	-4,070.10%	50.96%	65.22%	43.50%	256.26%	65.83%	23.51%	-19.61%
Net Income Growth	204.44%	1,319.18%	-651.08%	665.09%	21.31%	65.96%	156.66%	-31.94%	56.20%	-30.20%
EPS Growth	200.00%	1,400.00%	-664.29%	627.78%	18.84%	63.74%	153.16%	-33.68%	51.22%	-32.89%
Operating Cash Flow Growth	59.87%	3,304.76%	-209.14%	30.05%	114.57%	-13.64%	204.07%	-64.03%	-25.47%	96.36%
Free Cash Flow Firm Growth	52.85%	-552.29%	-16.69%	31.91%	124.19%	230.91%	274.83%	68.84%	-12.33%	-121.27%
Invested Capital Growth	52.52%	57.61%	26.99%	30.53%	12.76%	-11.45%	-39.23%	18.35%	15.77%	24.60%
Revenue Q/Q Growth	2.56%	6.21%	2.04%	7.68%	10.18%	3.29%	0.02%	14.54%	5.40%	0.90%
EBITDA Q/Q Growth	99.81%	14.16%	-191.76%	202.75%	-10.26%	77.63%	-93.23%	1,013.27%	32.67%	37.99%
EBIT Q/Q Growth	109.09%	11.83%	-201.27%	199.02%	-8.84%	77.35%	-93.20%	928.69%	32.99%	37.09%
NOPAT Q/Q Growth	60.44%	27.06%	-202.42%	172.31%	75.60%	10.35%	11.53%	-23.27%	30.79%	-28.18%
Net Income Q/Q Growth	505.33%	29.93%	-186.07%	224.67%	-12.98%	77.74%	-70.62%	49.77%	99.69%	-20.57%
EPS Q/Q Growth	483.33%	31.88%	-186.81%	220.25%	-13.68%	81.71%	-71.81%	50.00%	96.83%	-19.35%
Operating Cash Flow Q/Q Growth	-28.46%	44.74%	-187.55%	243.45%	18.04%	-41.75%	5.51%	-50.42%	144.58%	53.48%
Free Cash Flow Firm Q/Q Growth	17.96%	-6.59%	-69.17%	53.98%	129.15%	476.81%	125.92%	-108.20%	182.01%	-239.96%
Invested Capital Q/Q Growth	2.39%	6.65%	21.46%	-1.59%	-11.54%	-16.25%	-16.64%	91.64%	-13.48%	-9.86%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	98.43%	98.13%	97.98%	97.46%	97.75%	98.35%	98.54%	98.44%	98.71%	98.52%
EBITDA Margin	26.58%	28.57%	-25.95%	24.76%	20.17%	34.69%	2.19%	21.31%	26.83%	36.69%
Operating Margin	22.63%	25.10%	-27.16%	16.26%	28.31%	29.17%	19.27%	24.64%	29.55%	22.62%
EBIT Margin	25.50%	26.84%	-26.64%	24.50%	20.27%	34.80%	2.37%	21.26%	26.83%	36.45%
Profit (Net Income) Margin	17.66%	21.60%	-18.22%	21.10%	16.66%	28.67%	8.42%	11.01%	20.86%	16.43%
Tax Burden Percent	69.97%	75.49%	74.15%	78.54%	71.89%	74.52%	125.80%	65.92%	68.21%	63.41%
Interest Burden Percent	98.99%	106.60%	92.23%	109.65%	114.34%	110.54%	282.79%	78.57%	114.02%	71.07%
Effective Tax Rate	30.03%	24.51%	0.00%	21.46%	28.11%	25.48%	-25.80%	34.08%	31.79%	36.59%
Return on Invested Capital (ROIC)	48.15%	58.64%	-47.58%	34.39%	61.84%	73.95%	83.62%	44.82%	67.33%	57.73%
ROIC Less NNEP Spread (ROIC-NNEP)	47.43%	57.61%	-47.95%	30.68%	63.39%	71.42%	89.20%	47.01%	67.07%	57.02%
Return on Net Nonoperating Assets (RNNOA)	-32.44%	-39.63%	28.03%	-19.05%	-42.41%	-51.31%	-64.02%	-30.46%	-48.00%	-43.18%
Return on Equity (ROE)	15.71%	19.01%	-19.55%	15.34%	19.43%	22.64%	19.60%	14.37%	19.34%	14.56%
Cash Return on Invested Capital (CROIC)	-24.65%	-7.33%	-8.99%	-8.21%	14.37%	46.15%	112.39%	36.18%	49.18%	46.56%
Operating Return on Assets (OROA)	17.02%	18.00%	-18.91%	17.75%	14.49%	23.37%	1.61%	15.23%	18.85%	24.63%
Return on Assets (ROA)	11.79%	14.48%	-12.93%	15.28%	11.91%	19.25%	5.72%	7.89%	14.66%	11.10%
Return on Common Equity (ROCE)	15.71%	19.01%	-19.55%	15.34%	19.43%	22.64%	19.60%	14.37%	19.34%	14.56%
Return on Equity Simple (ROE_SIMPLE)	3.77%	0.00%	3.80%	9.52%	9.54%	0.00%	15.49%	13.52%	14.19%	0.00%
Net Operating Profit after Tax (NOPAT)	61	78	-80	58	102	112	125	96	125	90
NOPAT Margin	15.84%	18.95%	-19.02%	12.77%	20.35%	21.74%	24.24%	16.24%	20.15%	14.34%
Net Nonoperating Expense Percent (NNEP)	0.71%	1.03%	0.37%	3.71%	-1.55%	2.52%	-5.58%	-2.18%	0.26%	0.72%
Return On Investment Capital (ROIC_SIMPLE)	-	4.16%	-	-	-	4.66%	-	-	-	3.48%
Cost of Revenue to Revenue	1.57%	1.87%	2.02%	2.54%	2.25%	1.65%	1.46%	1.56%	1.29%	1.48%
SG&A Expenses to Revenue	48.03%	44.39%	57.73%	48.99%	40.94%	42.49%	47.18%	41.00%	37.66%	45.85%
R&D to Revenue	27.76%	28.64%	67.41%	32.21%	28.51%	26.69%	32.10%	32.80%	31.51%	30.05%
Operating Expenses to Revenue	75.79%	73.03%	125.14%	81.20%	69.45%	69.18%	79.27%	73.81%	69.17%	75.90%
Earnings before Interest and Taxes (EBIT)	99	111	-112	111	101	179	12	126	167	229
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	103	118	-109	112	101	179	11	126	167	230
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.58	6.72	5.80	4.97	5.49	5.80	5.68	5.52	4.28	5.34
Price to Tangible Book Value (P/TBV)	6.58	6.87	5.93	5.07	5.58	5.89	5.76	5.60	4.33	5.41
Price to Revenue (P/Rev)	7.31	7.71	6.12	5.50	6.16	6.86	6.84	6.54	5.19	5.87
Price to Earnings (P/E)	174.53	74.32	152.76	52.16	57.52	51.84	36.65	40.85	30.15	40.49
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.57%	1.35%	0.65%	1.92%	1.74%	1.93%	2.73%	2.45%	3.32%	2.47%
Enterprise Value to Invested Capital (EV/IC)	16.61	17.61	12.32	11.45	15.44	21.56	26.70	14.63	13.38	18.30
Enterprise Value to Revenue (EV/Rev)	6.60	6.96	5.51	4.81	5.38	5.95	5.85	5.75	4.30	5.04
Enterprise Value to EBITDA (EV/EBITDA)	48.67	34.65	53.54	35.79	43.17	39.80	28.75	29.20	19.93	22.23
Enterprise Value to EBIT (EV/EBIT)	56.82	37.04	60.82	38.64	45.61	40.22	28.75	29.13	19.91	22.27
Enterprise Value to NOPAT (EV/NOPAT)	118.43	57.62	93.20	70.95	62.08	59.55	31.75	29.92	22.50	29.65
Enterprise Value to Operating Cash Flow (EV/OCF)	45.69	30.53	34.58	27.18	23.46	28.81	17.97	22.96	20.23	19.95
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	113.89	43.88	17.96	43.82	29.19	43.61
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.11	0.10	0.10	0.09	0.08	0.08	0.05	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.68	-0.69	-0.58	-0.62	-0.67	-0.72	-0.72	-0.65	-0.72	-0.76
Leverage Ratio	1.44	1.44	1.46	1.41	1.41	1.43	1.43	1.36	1.35	1.45
Compound Leverage Factor	1.42	1.54	1.35	1.55	1.61	1.58	4.05	1.07	1.54	1.03
Debt to Total Capital	9.87%	9.02%	9.14%	8.39%	7.82%	7.08%	4.89%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	9.87%	9.02%	0.00%	8.39%	7.82%	7.08%	4.89%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	9.14%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	90.13%	90.98%	90.86%	91.61%	92.18%	92.92%	95.11%	100.00%	100.00%	100.00%
Debt to EBITDA	0.90	0.57	1.03	0.75	0.76	0.60	0.30	0.00	0.00	0.00
Net Debt to EBITDA	-5.27	-3.74	-5.89	-5.11	-6.20	-6.06	-4.84	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	1.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	2.19	0.94	1.79	1.50	1.10	0.90	0.34	0.00	0.00	0.00
Net Debt to NOPAT	-12.83	-6.22	-10.26	-10.13	-8.92	-9.07	-5.34	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	1.79	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	11.06	11.43	9.46	8.26	8.79	8.67	8.40	11.65	9.87	8.58
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.49	2.70	3.83	2.57	2.39	2.45	2.52	4.19	4.37	3.40
Quick Ratio	2.27	2.49	3.44	2.34	2.19	2.25	2.33	3.78	3.98	3.06
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-129	-137	-232	-107	31	179	405	-33	27	-38
Operating Cash Flow to CapEx	0.00%	7,944.44%	-1,472.94%	2,641.18%	2,789.47%	2,287.04%	1,163.39%	556.90%	1,950.62%	3,321.92%
Free Cash Flow to Firm to Interest Expense	-107.14	0.00	-210.76	0.00	0.00	0.00	368.47	-0.67	0.00	-0.44
Operating Cash Flow to Interest Expense	82.33	0.00	-113.82	0.00	0.00	0.00	118.45	1.30	0.00	2.77
Operating Cash Flow Less CapEx to Interest Expense	83.75	0.00	-121.55	0.00	0.00	0.00	108.27	1.07	0.00	2.68
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.67	0.67	0.71	0.72	0.71	0.67	0.68	0.72	0.70	0.68
Accounts Receivable Turnover	5.97	5.56	4.88	5.02	4.96	4.78	4.71	4.95	4.99	5.13
Inventory Turnover	0.63	0.71	0.87	1.11	1.18	1.08	1.10	0.98	0.89	0.71
Fixed Asset Turnover	24.80	25.40	25.23	25.27	27.51	29.17	28.70	29.09	30.15	30.71
Accounts Payable Turnover	0.08	0.08	0.09	0.10	0.10	0.10	0.10	0.10	0.07	0.07
Days Sales Outstanding (DSO)	61.11	65.65	74.79	72.72	73.56	76.33	77.56	73.69	73.14	71.16
Days Inventory Outstanding (DIO)	581.95	516.03	420.22	329.36	308.70	337.42	332.93	372.02	410.08	513.68
Days Payable Outstanding (DPO)	4,690.06	4,510.58	3,984.02	3,549.03	3,756.97	3,661.03	3,644.81	3,760.80	4,923.65	4,886.71
Cash Conversion Cycle (CCC)	-4,047.00	-3,928.90	-3,489.01	-3,146.95	-3,374.71	-3,247.28	-3,234.32	-3,315.10	-4,440.43	-4,301.86
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	552	589	715	703	622	521	434	833	720	649
Invested Capital Turnover	3.04	3.10	2.50	2.69	3.04	3.40	3.45	2.76	3.34	4.02
Increase / (Decrease) in Invested Capital	190	215	152	165	70	-67	-280	129	98	128
Enterprise Value (EV)	9,165	10,363	8,807	8,052	9,606	11,235	11,599	12,178	9,636	11,880
Market Capitalization	10,158	11,482	9,777	9,201	10,986	12,946	13,551	13,855	11,634	13,820
Book Value per Share	$16.15	$17.76	$17.44	$18.99	$20.50	$22.72	$23.91	$24.93	$26.93	$25.58
Tangible Book Value per Share	$16.15	$17.38	$17.05	$18.61	$20.14	$22.36	$23.57	$24.60	$26.58	$25.22
Total Capital	1,714	1,877	1,854	2,023	2,172	2,402	2,509	2,509	2,719	2,590
Total Debt	169	169	170	170	170	170	123	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	170	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-993	-1,119	-970	-1,150	-1,380	-1,711	-1,952	-1,677	-1,999	-1,940
Capital Expenditures (CapEx)	-1.70	1.80	8.50	6.80	7.60	5.40	11	12	8.10	7.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	90	96	164	107	33	91	-1.70	232	219	141
Debt-free Net Working Capital (DFNWC)	890	1,085	1,059	1,084	1,128	1,122	1,209	1,271	1,447	1,217
Net Working Capital (NWC)	720	916	1,059	914	958	952	1,086	1,271	1,447	1,217
Net Nonoperating Expense (NNE)	-7.07	-11	-3.34	-38	18	-36	82	31	-4.43	-13
Net Nonoperating Obligations (NNO)	-993	-1,119	-970	-1,150	-1,380	-1,711	-1,952	-1,677	-1,999	-1,940
Total Depreciation and Amortization (D&A)	4.20	7.10	2.90	1.20	-0.50	-0.60	-0.90	0.30	0.00	1.50
Debt-free, Cash-free Net Working Capital to Revenue	6.50%	6.44%	10.27%	6.40%	1.86%	4.81%	-0.09%	10.96%	9.76%	5.98%
Debt-free Net Working Capital to Revenue	64.06%	72.90%	66.23%	64.78%	63.24%	59.47%	60.99%	59.98%	64.51%	51.67%
Net Working Capital to Revenue	51.88%	61.52%	66.23%	54.64%	53.72%	50.46%	54.80%	59.98%	64.51%	51.67%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.72	$0.92	($0.79)	$0.98	$0.85	$1.52	$0.43	$0.64	$1.28	$1.05
Adjusted Weighted Average Basic Shares Outstanding	95.80M	95.80M	97.10M	97.60M	97.90M	97.70M	99.80M	100.80M	101.10M	100.40M
Adjusted Diluted Earnings per Share	$0.69	$0.91	($0.79)	$0.95	$0.82	$1.49	$0.42	$0.63	$1.24	$1.00
Adjusted Weighted Average Diluted Shares Outstanding	99M	98.90M	97.10M	100.20M	101.10M	101M	103.60M	103.90M	104.30M	103.70M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	96.13M	96.59M	97.57M	97.65M	98.25M	99.51M	100.64M	100.98M	101.25M	99.70M
Normalized Net Operating Profit after Tax (NOPAT)	61	78	-80	58	102	112	70	96	125	90
Normalized NOPAT Margin	15.84%	18.95%	-19.02%	12.77%	20.35%	21.74%	13.49%	16.24%	20.15%	14.34%
Pre Tax Income Margin	25.24%	28.62%	-24.57%	26.86%	23.18%	38.47%	6.70%	16.71%	30.59%	25.90%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	82.42	0.00	-101.82	0.00	0.00	0.00	11.09	2.53	0.00	2.61
NOPAT to Interest Expense	51.19	0.00	-72.67	0.00	0.00	0.00	113.56	1.93	0.00	1.03
EBIT Less CapEx to Interest Expense	83.83	0.00	-109.55	0.00	0.00	0.00	0.91	2.29	0.00	2.53
NOPAT Less CapEx to Interest Expense	52.61	0.00	-80.40	0.00	0.00	0.00	103.38	1.70	0.00	0.94
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	87.90%

Frequently Asked Questions About Neurocrine Biosciences' Financials

When does Neurocrine Biosciences's fiscal year end?

According to the most recent income statement we have on file, Neurocrine Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Neurocrine Biosciences' net income changed over the last 9 years?

Neurocrine Biosciences' net income appears to be on an upward trend, with a most recent value of $341.30 million in 2024, falling from -$88.93 million in 2015. The previous period was $249.70 million in 2023. View Neurocrine Biosciences' forecast to see where analysts expect Neurocrine Biosciences to go next.

What is Neurocrine Biosciences's operating income?

Neurocrine Biosciences's total operating income in 2024 was $570.50 million, based on the following breakdown:

Total Gross Profit: $2.32 billion
Total Operating Expenses: $1.75 billion

How has Neurocrine Biosciences revenue changed over the last 9 years?

Over the last 9 years, Neurocrine Biosciences' total revenue changed from $19.77 million in 2015 to $2.36 billion in 2024, a change of 11,814.1%.

How much debt does Neurocrine Biosciences have?

Neurocrine Biosciences' total liabilities were at $1.13 billion at the end of 2024, a 10.8% increase from 2023, and a 2,143.2% increase since 2015.

How much cash does Neurocrine Biosciences have?

In the past 9 years, Neurocrine Biosciences' cash and equivalents has ranged from $74.20 million in 2015 to $340.80 million in 2021, and is currently $233 million as of their latest financial filing in 2024.

How has Neurocrine Biosciences' book value per share changed over the last 9 years?

Over the last 9 years, Neurocrine Biosciences' book value per share changed from 4.92 in 2015 to 25.58 in 2024, a change of 419.4%.

Related Companies

This page (NASDAQ:NBIX) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neurocrine Biosciences (NBIX) Financials

Frequently Asked Questions About Neurocrine Biosciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neurocrine Biosciences (NBIX) Financials

Annual Income Statements for Neurocrine Biosciences

Quarterly Income Statements for Neurocrine Biosciences

Annual Cash Flow Statements for Neurocrine Biosciences

Quarterly Cash Flow Statements for Neurocrine Biosciences

Annual Balance Sheets for Neurocrine Biosciences

Quarterly Balance Sheets for Neurocrine Biosciences

Annual Metrics and Ratios for Neurocrine Biosciences

Quarterly Metrics and Ratios for Neurocrine Biosciences

Frequently Asked Questions About Neurocrine Biosciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools